TechNavio's analysts forecast the Global Hyperphosphatemia Drugs market to grow at a CAGR of 12.5 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of chronic kidney disease. The Global Hyperphosphatemia Drugs market has also been witnessing the trend of an increasing number of strategic alliances among vendors. However, side effects caused by the hyperphosphatemia drugs could pose a challenge to the growth of this market.
TechNavio's report, the Global Hyperphosphatemia Drugs Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hyperphosphatemia Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include Fresenius Medical Care AG & Co. KGaA, Shire plc, and Sanofi S.A.
Other vendors mentioned in the report: Keryx Biopharmaceuticals Inc., Novartis AG, Vifor Pharma AG, Astellas Pharma Inc., Panacor Bioscience Ltd., and Perrigo Co.
You can request one free hour of analyst time when you purchase this report. Details provided within the report.